Trial Profile

A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bladder cancer; Bone metastases; Germ cell and embryonal neoplasms; Germ cell cancer; Penile cancer; Primitive neuroectodermal tumours; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Testicular cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

13 Feb 2025 Planned End Date changed from 30 Sep 2024 to 30 Sep 2026.
13 Feb 2025 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2026.
03 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com